EurekaMag.com logo
+ Site Statistics
References:
47,893,527
Abstracts:
28,296,643
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Oral antidiabetic combination therapy with sulphonylureas and metformin






Diabete & Metabolisme 17(1 Pt 2): 224-231

Oral antidiabetic combination therapy with sulphonylureas and metformin

In a multicentre trial in general practice, a total of 1823 type 2 diabetics, not adequately controlled by diet and maximal sulphonylurea therapy, were treated with additional metformin 850--2 550 mg/d for 12 weeks. The average postprandial blood sugar decreased from 15.48 mmol/l to 10.43 mmol/l, HbA1 fell from 11.0% to 9.1%. Serum triglycerides decreased from an initial level of 2.87 mmol/l to 2.41 mmol/l an mean total cholesterol from 6.76 mmol/l to 6.16 mmol/l. In addition, body weight and blood pressure declined steadily. All the described changes were statistically significant. The metformin-sulphonylurea combination therapy was generally well tolerated. Gastrointestinal side effects occurred in about 7% of patients, but mainly in the first week of treatment, generally disappearing spontaneous as therapy was continued. Side effects led to a discontinuation of the treatment in 4.2% of patients.


Accession: 040874534

PMID: 1936481



Related references

Morgan, C.Ll.; Mukherjee, J.; Jenkins-Jones, S.; Holden, S.E.; Currie, C.J., 2015: Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality. To compare the risk of major adverse cardiovascular events (MACE) and mortality for combination therapies with metformin and either sulphonylurea (SU) or dipeptidyl peptidase-4 inhibitor (DPP-4i). Data were from the UK Clinical Practice Research D...

Barner, J.C., 2012: Adherence to oral antidiabetic agents with pioglitazone and metformin: comparison of fixed-dose combination therapy with monotherapy and loose-dose combination therapy. Studies have examined adherence when switching from loose-dose combination therapy (LDCT) to fixed-dose combination therapy (FDCT) among oral antidiabetic agents. However, little is known regarding combination therapies, including pioglitazone and...

Ionova, T.; Nikitina, T.; Kurbatova, K.; Rodionova, A., 2015: Benefits And Risks of Vildagliptin/Metformin Versus Sulphonylureas/Metformin Combination Therapy In Type 2 Diabetes Mellitus (T2dm) From Patient's Perspective: Real-World Data. Value in Health 18(7): A615-A615

Derosa, G.; Salvadeo, S.A.T.; D'Angelo, A.; Ferrari, I.; Mereu, R.; Palumbo, I.; Maffioli, P.; Randazzo, S.; Cicero, A.F.G., 2010: Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial. To compare the metabolic effects of acarbose and repaglinide in type 2 diabetic patients who are being treated with a sulphonylurea-metformin combination therapy. The primary endpoint of the study was to evaluate which add-on treatment between aca...

Schöffling, K., 1971: Clinical experiences in oral antidiabetic therapy with sulphonylureas and biguanides. Australian and New Zealand Journal of Medicine 1: Suppl 2:47-56

Anonymous, 2007: New class of oral antidiabetic drugs. Effective in combination with metformin. Mmw Fortschritte der Medizin 149(1-2): 17-17

Melikian, C.; White, T.Jeffrey.; Vanderplas, A.; Dezii, C.M.; Chang, E., 2002: Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Although medication adherence is one of the most important aspects of the management of diabetes mellitus, low rates of adherence have been documented. This study sought to examine medication adherence among patients with diabetes mellitus in a ma...

Melikian, C.; White, T.J.ffrey; Vanderplas, A.; Dezii, C.M.; Chang, E., 2002: Adherence to oral antidiabetic therapy in a managed care organization: A comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Background: Although medication adherence is one of the most important aspects of the management of diabetes mellitus, low rates of adherence have been documented. Objective: This study sought to examine medication adherence among patients with di...

Karim, A.; Slater, M.; Bradford, D.; Schwartz, L.; Laurent, A., 2006: Oral antidiabetic drugs: effect of food on absorption of pioglitazone and metformin from a fixed-dose combination tablet. An open-label, randomized, crossover study involving 28 healthy subjects was conducted to compare the peak (C-max) and total (AUC(lqc), AUC(infinity)) exposures to pioglitazone and metformin after single-dose administration of a fixed-dose combin...

Kokić, S.; Buković, D.; Radman, M.; Capkun, V.; Gabrić, N.; Lesko, V.; Karelović, D.; Stancerić, T., 2003: Lispro insulin and metformin versus other combination in the diabetes mellitus type 2 management after secondary oral antidiabetic drug failure. The purpose of the study was to find out differences between treatments of diabetes type 2 after secondary oral antidiabetic drug failure. Three different methods of treatment were compared: lispro insulin in combination with metformin, glimepirid...